Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor Hematopoietic Cell Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignan

 


A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor Hematopoietic Cell Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignan


Trial Focus

Blood Diseases (Except Leukemia)

Objective

         This research study looks at ways to prevent a common but very serious complication following transplantation called "graft versus host disease" or "GVHD." . The purpose of this study is to evaluate three different combinations of th

IRB Protocol #

11-0199

Trial Status

OPEN

Principle Investigator

JONATHAN GUTMAN

Sponsor

Fred Hutchinson Cancer Research Center

Contact

DEREK SCHATZ at (720)848-0628 or DEREK.SCHATZ@UCDENVER.EDU

Location

University of Colorado Hospital University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : Following a screening period to determine study eligibility, your treatment will last for approximately 6 months. We will have you back for follow up 6 months later and again every year thereafter in order to help manage some of the complications of the transplant. We would like to keep track of your medical condition for the rest of your life to fully understand the long-term effects of this study; however, you may be taken off the study for various reasons. // Eligibility criteria include but are not limited to: 18yrs. of age or older with Hematologic Malignancies. Eligibility criteria include but are not limited to: 18yrs. of age or older with Hematologic Malignancies.